The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Open accessAbstract
Tumor-targeted 4-1BB agonists provide costimulation as combination partners for cancer immunotherapies in solid and hematological tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
Development and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789 · cited 1×
“No immune cell accumulation in the liver occurred; however, the low efficiency of myeloid cell engraftment of the HSC-NSG mice model (34) may not completely reflect a fully immunocompetent setting.”
BackgroundGeorgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Eck, M. J., & Sprang, S. R. (1990) · PubMed · doi:10.2210/pdb1tnf/pdb · Cited by 507
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Self-citationThe Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution
Eck, M. J., & Sprang, S. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71533-0 · Cited by 473
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw040 · Cited by 425
Self-citationResults from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1272 · Cited by 424
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Self-citationEffector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 323
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Saoulli, K., Lee, S. Y., Cannons, J. L., Yeh, W. C., Santana, A., Goldstein, M. D., Bangia, N., DeBenedette, M. A., Mak, T. W., Choi, Y., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1849 · Cited by 322
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 299
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Bacac, M., Colombetti, S., Herter, S., Sam, J., Perro, M., Chen, S., Bianchi, R., Richard, M., Schoenle, A., Nicolini, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0455 · Cited by 249
Self-citationBispecific antibodies for cancer therapy: A review
Krishnamurthy, A., & Jimeno, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.002 · Cited by 223
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
Bispecific human IgG by design
Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167
Denton, A. E., Roberts, E. W., Linterman, M. A., & Fearon, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412910111 · Cited by 164
Principles of antibody-mediated TNF receptor activation
Wajant, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.109 · Cited by 161
Hinner, M. J., Aiba, R. S. B., Jaquin, T. J., Berger, S., Dürr, M. C., Schlosser, C. S., Allersdorfer, A., Wiedenmann, A., Matschiner, G., Schüler, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3654 · Cited by 161
van Muijen, G. N. P., Jansen, K. F. J., Cornelissen, I. M. H. A., Smeets, D. F. C. M., Beck, J. L. M., & Ruiter, D. J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910480116 · Cited by 159
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 153
Compte, M., Harwood, S. L., Muñoz, I. G., Navarro, R., Zonca, M., Pérez-Chacón, G., Erce-Llamazares, A., Merino, N., Tapia‐Galisteo, A., Cuesta, Á. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07195-w · Cited by 153
The Crystal Structure of the Costimulatory OX40-OX40L Complex
Compaan, D. M., & Hymowitz, S. G. (2006) · Structure · doi:10.1016/j.str.2006.06.015 · Cited by 150
4-1BB signaling beyond T cells
Vinay, D. S., & Kwon, B. S. (2011) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.82 · Cited by 149
Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.
Clarke, P., Mann, J. R., Simpson, J. F., Rickard-Dickson, K. J., & Primus, F. J. (1998) · PubMed · Cited by 148
Hernandez-Chacon, J. A., Li, Y., Wu, R. C. H., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P., & Radvanyi, L. G. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209e7ec · Cited by 141
DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 135
Bacac, M., Klein, C., & Umaña, P. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1203498 · Cited by 119
Self-citationA mechanistic compartmental model for total antibody uptake in tumors
Thurber, G. M., & Wittrup, K. D. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.08.034 · Cited by 116
Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martínez‐Forero, I., Perez‐Gracia, J. L., Morales‐Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás‐Stubbs, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0846-9 · Cited by 115
Li, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 115
Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M., & Chen, L. (2003) · Blood · doi:10.1182/blood-2003-06-2184 · Cited by 108
Xu, Y., Szalai, A. J., Zhou, T., Zinn, K. R., Chaudhuri, T. R., Li, X., Koopman, W. J., & Kimberly, R. P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.562 · Cited by 108
The Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 108
Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma
Ghanem, G., & Journé, F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.006 · Cited by 106
Juillerat‐Jeanneret, L., Tafelmeyer, P., & Golshayan, D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1370455 · Cited by 71
Levitsky, V., de Campos-Lima, P. O., Frisan, T., & Masucci, M. G. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.594 · Cited by 61
Self-citationEx-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments
Muraro, M. G., Muenst, S. E., Mele, V., Quagliata, L., Iezzi, G., Tzankov, A., Weber, W. P., Spagnoli, G. C., & Soysal, S. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331798 · Cited by 52
Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand
Kang, S. W., Lee, S. C., Park, S. H., Kim, J., Kim, H. H., Lee, H., Seo, S. K., Kwon, B. S., Cho, H. R., & Kwon, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0610 · Cited by 52
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Aznar, M. A., Labiano, S., Díaz‐Lagares, Á., Molina, C., Garasa, S., Azpilikueta, A., Etxeberría, I., Sánchez-Paulete, A. R., Korman, A. J., Esteller, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0159 · Cited by 44
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy
Pérez-Ruiz, E., Etxeberría, I., Rodriguez-Ruiz, M. E., & Melero, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1799 · Cited by 40
Fellermeier, S., Beha, N., Meyer, J.-E., Ring, S., Bader, S., Kontermann, R. E., & Müller, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238540 · Cited by 34
Regula, J. T., Imhof-Jung, S., Mølhøj, M., Benz, J., Ehler, A., Bujotzek, A., Schäfer, W. M., & Klein, C. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy021 · Cited by 34
Self-citationCrystal structure of the human 4-1BB/4-1BBL complex
Gilbreth, R. N., Oganesyan, V., Amdouni, H., Novarra, S., Grinberg, L., Barnes, A. S., & Baca, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002803 · Cited by 32
Argilés, G., Saro, J., Segal, N. H., Melero, I., Ros, W., Marabelle, A., Rodríguez, M. E., Albanell, J., Calvo, E., Moreno, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx302.003 · Cited by 29
Self-citationCD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
Bacac, M., Umaña, P., Herter, S., Colombetti, S., Sam, J., Clech, M. L., Freimoser–Grundschober, A., Richard, M., Nicolini, V., Gerdes, C. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1836.1836 · Cited by 26
Self-citation
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
Self-citationT-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 267
Metadata
- Authors
- Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., Diggelmann, S., Challier, J., Mössner, E., Hosse, R. J., Hofer, T., Brünker, P., Joseph, C., Benz, J., Ringler, P., Stahlberg, H., Lauer, M., Perro, M., Chen, S., Küttel, C., Bhavani Mohan, P. L., Nicolini, V., Birk, M. C., Ongaro, A., Prince, C., Gianotti, R., Dugan, G., Whitlow, C. T., Solingapuram Sai, K. K., Caudell, D. L., Burgos-Rodriguez, A. G., Cline, J. M., Hettich, M., Ceppi, M., Giusti, A. M., Crameri, F., Driessen, W., Morcos, P. N., Freimoser-Grundschober, A., Levitsky, V., Amann, M., Grau-Richards, S., von Hirschheydt, T., Tournaviti, S., Mølhøj, M., Fauti, T., Heinzelmann-Schwarz, V., Teichgräber, V., Colombetti, S., Bacac, M., Zippelius, A., Klein, C., & Umaña, P.
- Venue
- Science Translational Medicine
- Published
- 2019-06-12
- Volume
- 11
- Issue
- 496
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2952816064
- Cited by
- 270
- References
- 57
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.